Literature DB >> 10775627

Transdominant activity of human immunodeficiency virus type 1 Vpr with a mutation at residue R73.

B E Sawaya1, K Khalili, J Gordon, A Srinivasan, M Richardson, J Rappaport, S Amini.   

Abstract

The 96-amino-acid-long human immunodeficiency virus type 1 virion-encoded accessory protein Vpr is of particular interest, as this protein, which is found in association with viral particles, can exert a regulatory effect on both virus replication and host cell function. Evidently, Vpr, through interaction with several host regulatory proteins, can modulate transcription from the viral long terminal repeat promoter. Expression of Vpr in cells results in deregulation of cell proliferation during the cell cycle pathway at the G(2) stage. Vpr has unique structural features consisting of multiple functional domains. In this study, we have focused on the leucine/isoleucine-rich domain near the carboxyl terminus of Vpr at residue 73 (arginine) and have demonstrated that alterations at this residue result in ablation of transcriptional activity of Vpr and its ability to block cell cycle events at the G(2) stage. Interestingly, substitution mutations at R73 have resulted in a peptide with dominant negative activities on wild-type functions in transcription and host proliferation events. Results from in vitro and in vivo protein-protein interaction studies have revealed that functionally inactive mutant Vpr can be associated with wild-type protein, presumably through the N-terminal regions of the protein which have been shown to be important for Vpr oligomerization. Thus, it is likely that complexation of the mutant Vpr with wild-type protein functionally inactivates Vpr. The importance of these findings in light of the development of therapeutic strategies is discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10775627      PMCID: PMC112011          DOI: 10.1128/jvi.74.10.4877-4881.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

Review 1.  HIV-1 auxiliary proteins: making connections in a dying cell.

Authors:  B R Cullen
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

2.  HIV transcriptional activation by the accessory protein, VPR, is mediated by the p300 co-activator.

Authors:  L K Felzien; C Woffendin; M O Hottiger; R A Subbramanian; E A Cohen; G J Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

3.  Suppression of HIV-1 transcription and replication by a Vpr mutant.

Authors:  B E Sawaya; K Khalili; J Rappaport; D Serio; W Chen; A Srinivasan; S Amini
Journal:  Gene Ther       Date:  1999-05       Impact factor: 5.250

4.  Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation.

Authors:  X J Yao; R A Subbramanian; N Rougeau; F Boisvert; D Bergeron; E A Cohen
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

5.  Structural studies of synthetic peptide fragments derived from the HIV-1 Vpr protein.

Authors:  Z Luo; D J Butcher; R Murali; A Srinivasan; Z Huang
Journal:  Biochem Biophys Res Commun       Date:  1998-03-27       Impact factor: 3.575

Review 6.  HIV-1, Vpr and the cell cycle.

Authors:  M Emerman
Journal:  Curr Biol       Date:  1996-09-01       Impact factor: 10.834

7.  Human immunodeficiency virus type 1 (HIV-1) viral protein R (Vpr) interacts with Lys-tRNA synthetase: implications for priming of HIV-1 reverse transcription.

Authors:  L A Stark; R T Hay
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme.

Authors:  M Bouhamdan; S Benichou; F Rey; J M Navarro; I Agostini; B Spire; J Camonis; G Slupphaug; R Vigne; R Benarous; J Sire
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

9.  HHR23A, the human homologue of the yeast repair protein RAD23, interacts specifically with Vpr protein and prevents cell cycle arrest but not the transcriptional effects of Vpr.

Authors:  A Gragerov; T Kino; G Ilyina-Gragerova; G P Chrousos; G N Pavlakis
Journal:  Virology       Date:  1998-06-05       Impact factor: 3.616

10.  Mutational analysis of cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency virus type 1 Vpr.

Authors:  P Di Marzio; S Choe; M Ebright; R Knoblauch; N R Landau
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

View more
  14 in total

1.  Biochemical analyses of the interactions between human immunodeficiency virus type 1 Vpr and p6(Gag).

Authors:  Y Jenkins; O Pornillos; R L Rich; D G Myszka; W I Sundquist; M H Malim
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

2.  Critical role for antiapoptotic Bcl-xL and Mcl-1 in human macrophage survival and cellular IAP1/2 (cIAP1/2) in resistance to HIV-Vpr-induced apoptosis.

Authors:  Aurelia Busca; Mansi Saxena; Ashok Kumar
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

3.  The mitochondriotoxic domain of Vpr determines HIV-1 virulence.

Authors:  Catherine Brenner; Guido Kroemer
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

4.  Human immunodeficiency virus type 1 Vpr-dependent cell cycle arrest through a mitogen-activated protein kinase signal transduction pathway.

Authors:  Naoto Yoshizuka; Yuko Yoshizuka-Chadani; Vyjayanthi Krishnan; Steven L Zeichner
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

5.  SIV Vpr evolution is inversely related to disease progression in a morphine-dependent rhesus macaque model of AIDS.

Authors:  Richard J Noel; Anil Kumar
Journal:  Virology       Date:  2006-10-24       Impact factor: 3.616

6.  HIV-1 Vpr disrupts mitochondria axonal transport and accelerates neuronal aging.

Authors:  Ying Wang; Maryline Santerre; Italo Tempera; Kayla Martin; Ruma Mukerjee; Bassel E Sawaya
Journal:  Neuropharmacology       Date:  2017-02-14       Impact factor: 5.250

7.  Critical implication of the (70-96) domain of human immunodeficiency virus type 1 Vpr protein in apoptosis of primary rat cortical and striatal neurons.

Authors:  Emmanuelle N Sabbah; Bernard P Roques
Journal:  J Neurovirol       Date:  2005-12       Impact factor: 2.643

8.  Transmitted/Founder HIV-1 Subtype C Viruses Show Distinctive Signature Patterns in Vif, Vpr, and Vpu That Are Under Subsequent Immune Pressure During Early Infection.

Authors:  Raabya Rossenkhan; Iain J MacLeod; Zabrina L Brumme; Craig A Magaret; Theresa K Sebunya; Rosemary Musonda; Berhanu A Gashe; Paul T Edlefsen; Vlad Novitsky; M Essex
Journal:  AIDS Res Hum Retroviruses       Date:  2016-07-26       Impact factor: 2.205

9.  Novel macromolecular inhibitors of human immunodeficiency virus-1 protease.

Authors:  Gabriella Miklóssy; József Tözsér; János Kádas; Rieko Ishima; John M Louis; Péter Bagossi
Journal:  Protein Eng Des Sel       Date:  2008-05-13       Impact factor: 1.650

10.  Inhibitory Effects of HIV-2 Vpx on Replication of HIV-1.

Authors:  Mohamed Mahdi; Zsófia Szojka; János András Mótyán; József Tőzsér
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.